<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="478228" id="root" date="1997-04-01" xml:lang="en">
<title>USA: Boston Life Sciences completes enrollment.</title>
<headline>Boston Life Sciences completes enrollment.</headline>
<dateline>BOSTON 1997-04-01</dateline>
<text>
<p>Boston Life Sciences Inc said on Tuesday that it has completed patient enrollment in its Phase III trial for Therafectin, the company's oral drug for the treatment of Rheumatoid Arthritis.</p>
<p>The company said that all required patients had been enrolled into the double-blind, placebo-controlled trial and based on the 20 week duration of the study, results are expected to be available in the second half of 1997.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-04-01"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-04-01"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="BOSTON"/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
